Strategies to Optimize Treatment for Locally Advanced Rectal Cancer.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Neoadjuvant long-course concurrent chemoradiation plus surgery, followed by optional adjuvant chemotherapy, is a standard of care for locally advanced rectal cancer (LARC). However, this traditional approach has several limitations, including low pathological complete response (pCR) (10-25%), high metastasis rate (30-35%), and highly inconsistent compliance with adjuvant chemotherapy (25-75%). Treatment modalities for LARC have dramatically evolved in recent years. Multiple clinical trials have focused on optimizing strategies to achieve a win-win situation for oncologic outcomes and functions. Here, we review the latest studies into optimizing neoadjuvant treatment for LARC.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Cancers (Basel)

Title: Cancers

Publisher: MDPI AG

ISSN: 2072-6694

ISSN (Print): 2072-6694

Publication date (Electronic): Dec 29 2022

Volume: 15

Issue: 1

Affiliations

[1 ] Department of Oncology, Renmin Hospital of Wuhan University, Wuhan 430064, China.

[2 ] Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Science, Jinan 250117, China.

Article

Publisher Item ID: cancers15010219

DOI: 10.3390/cancers15010219

PMC ID: 9818694

PubMed ID: 36612213

SO-VID: 06e86f55-41b1-4e0a-b93d-677f78297cf6

History

Keywords: SCRT,TNT,immunotherapy,radiation therapy,LARC

Data availability:

Keywords: SCRT, TNT, immunotherapy, radiation therapy, LARC

Comments

Comment on this article

scite_

Cited by 2

See all cited by